Titre :
  • 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial
Auteur : Goldhirsch, Aron ; Gelber, Richard ; Piccart-Gebhart, Martine ; Azambuja, Evandro ; Dal Lago, Lissandra ; Procter, Marion ; McFadden, Eleanor E. ; Suter, Thomas ; Jackisch, Christian ; Cameron, David A ; Weber, Harald H.A. ; Heinzmann, Dominik D. ; Dowsett, Mitch ; Untch, Michael ; Gianni, Luca ; Bell, Richard R. ; Köhne, Claus Henning ; Vindevoghel, Anita ; Andersson, Michael M. ; Brunt, Adrian Murray A.M. ; Otero-Reyes, Douglas D. ; Song, Santai S. ; Smith, Ian ; Leyland-Jones, Brian ; Baselga, José
Informations sur la publication : Lancet, 382, 9897, (page 1021-1028)
Statut de publication : Publié, 2013
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adult
Aged
Antibodies, Monoclonal, Humanized -- administration & dosage -- adverse effects
Antineoplastic Agents -- administration & dosage -- adverse effects
Breast Neoplasms -- drug therapy
Chemotherapy, Adjuvant
Disease-Free Survival
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Medication Adherence
Middle Aged
Receptor, ErbB-2 -- metabolism
Treatment Outcome
Note : SCOPUS: ar.j
Langue :
  • Anglais
Identificateurs : urn:issn:0140-6736 
info:doi/10.1016/S0140-6736(13)61094-6
info:pii/S0140673613610946
info:pmid/23871490